Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Abeona Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Dise

americanpharmaceuticalreviewMarch 19, 2018

Tag: FDA , Abeona

PharmaSources Customer Service